AlphAIAlphAI — Financial news for AI agents
stockstotrade.comSEP 243 min read$TWST

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 8.35% after partnering with Eli Lilly for AI drug discovery. The company provides antibody data for Lilly's AI platform, boosting investor optimism. TWST's revenue grew to $376.6M, but it remains unprofitable. Analysts raised price targets, citing AI opportunities.

Original reporting
stockstotrade.com
Published Sep 24, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 4:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal — source image
Source · stockstotrade.com
Decision brief

The 30-second read

$TWSTBullishMed
01

Why it matters

The Lilly deal is the primary catalyst for the recent price surge and analyst upgrade.

02

Market read

A material partnership that could reshape revenue outlook for TWST and influence AI‑biotech sentiment.

03

What to watch

Execution risk of scaling wet‑lab services and potential competition from other synthetic biology firms.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Twist Bioscience is a high‑growth synthetic‑biology company with recent AI‑focused collaborations.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience announced a partnership with Eli Lilly to provide antibody data for Lilly's AI/ML TuneLab platform, driving an 8.35% price jump.

Expected impact

Potential upside of 10‑15% over the next few weeks if the collaboration scales.

Evidence & confidence

Analyst upgrade and immediate price reaction indicate market expects material revenue upside.

Market effects

Sector

Highlights growing convergence of synthetic biology and AI in biotech, may lift peer AI‑driven biotech stocks.

Regional

Positive for US biotech sector; limited broader market effect.

Global

Shows major pharma (Eli Lilly) adopting external AI data sources, relevant to global pharma AI adoption trends.

Counterpoint

What could challenge this read

The partnership may be limited in scope and revenue, and TWST's high burn rate could offset upside.

Key entities

  • Company
    Twist Bioscience

    US‑listed synthetic‑biology firm (NASDAQ: TWST).

  • Company
    Eli Lilly

    Pharma giant partnering with Twist for AI drug discovery.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Shares Soar 10.27% to New High, Extending a Remarkable 493% Yearlong Rally Fueled by AI

Twist Bioscience Corp. shares rose 10.27% to $174.78, extending a 493% yearlong rally. The surge follows a data-services agreement with Eli Lilly's AI-driven drug discovery platform, TuneLab. The company raised full-year revenue guidance to $456M-$457M and aims for adjusted EBITDA breakeven by Q4. Despite strong growth, Twist remains unprofitable with a negative EBIT margin of 31.5%.

ibtimes.com.au2 min
SEP 19
$TWSTHigh

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

timothysykes.com2 min